Pharmacogenetics of paraoxonases: a brief review
Top Cited Papers
- 1 January 2004
- journal article
- review article
- Published by Springer Nature in Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie
- Vol. 369 (1) , 78-88
- https://doi.org/10.1007/s00210-003-0833-1
Abstract
The human paraoxonase (PON) gene family consists of three members, PON1, PON2, and PON3, aligned next to each other on chromosome 7. By far the most-studied member of the family is the serum paraoxonase 1 (PON1), a high-density lipoprotein-associated esterase/lactonase. Early research focused on its capability to hydrolyze toxic organophosphates, and its name derives from one of its most commonly used in vitro substrates, paraoxon. Studies in the last 2 decades have demonstrated PON1’s ability to protect against atherosclerosis by hydrolyzing specific derivatives of oxidized cholesterol and/or phospholipids in oxidized low-density lipoprotein and in atherosclerotic lesions. Levels and genetic variability of PON1 influence sensitivity to specific insecticides and nerve agents, as well as the risk of cardiovascular disease. More recently, the other two members of the PON family, PON2 and PON3, have also been shown to have antioxidant properties. A major goal in present research on the paraoxonases is to identify their natural substrates and to elucidate the mechanism(s) of their catalytic activities.Keywords
This publication has 77 references indexed in Scilit:
- Future Studies of Low-Activity PON1 Phenotype Subjects May Reveal How PON1 Protects Against Cardiovascular DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Paraoxonase Activity, But Not Haplotype Utilizing the Linkage Disequilibrium Structure, Predicts Vascular DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Functional Genomics of the Paraoxonase (PON1) Polymorphisms: Effects on Pesticide Sensitivity, Cardiovascular Disease, and Drug MetabolismAnnual Review of Medicine, 2003
- Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controlsEuropean Journal of Clinical Investigation, 2002
- Proinflammatory Cytokines But Not Acute Phase Serum Amyloid A Or C-Reactive Protein, Downregulate Paraoxonase 1 (Pon1) Expression By Hepg2 CellsAmyloid, 2002
- Paraoxonase 1 192 Gln/Arg gene polymorphism and cerebrovascular disease: interaction with type 2 diabetesExperimental and Clinical Endocrinology & Diabetes, 2001
- Association of Low PON1 Type Q (Type A) Arylesterase Activity with Neurologic Symptom Complexes in Gulf War VeteransToxicology and Applied Pharmacology, 1999
- Paraoxonase Active Site Required for Protection Against LDL Oxidation Involves Its Free Sulfhydryl Group and Is Different From That Required for Its Arylesterase/Paraoxonase ActivitiesArteriosclerosis, Thrombosis, and Vascular Biology, 1998
- The Genetic Mapping and Gene Structure of Mouse Paraoxonase/ArylesteraseGenomics, 1995
- Plasma lipoprotein-associated arylesterase is induced by bacterial lipopolysaccharideFEBS Letters, 1978